

Sarah R Leist

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4784266/sarah-r-leist-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

7,159
citations

27
h-index

62
g-index

62
ext. papers

9,809
ext. citations

17.2
avg, IF

6
L-index

#	Paper	IF	Citations
54	Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV-RNAi expression vectors.. <i>Molecular Therapy</i> , 2022 ,	11.7	1
53	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , 2021 , 37, 109929	10.6	18
52	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	171
51	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice 2021 ,		11
50	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. <i>PLoS Pathogens</i> , 2021 , 17, e1009287	7.6	8
49	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice 2021 ,		5
48	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. <i>Nature</i> , 2021 , 591, 451-457	50.4	131
47	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021 , 36, 109450	10.6	23
46	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , 2021 , 54, 1869-1882.e6	32.3	16
45	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021 , 373, 991-998	39.3	48
44	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021 , 95, e0097421	6.6	3
43	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2021 , 17, e1009897	7.6	11
42	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021 , 184, 5432-5447.e16	56.2	34
41	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. <i>JCI Insight</i> , 2021 , 6,	9.9	22
40	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2020 , 8,	5.3	38
39	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , 2020 , 182, 429-446.e14	56.2	710
38	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020 , 32, 107940	10.6	260

37	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	534
36	Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice 2020 ,		15
35	A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures 2020 ,		58
34	Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models 2020 ,		19
33	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness 2020 ,		62
32	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate 2020 ,		8
31	A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine 2020 ,		13
30	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 2020 ,		10
29	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection 2020 ,		21
28	SARS-CoV-2 D614G Variant Exhibits Enhanced Replication and Earlier Transmission 2020 ,		41
27	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <i>Nature Communications</i> , 2020 , 11, 222	17.4	1059
26	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. <i>Nature</i> , 2020 , 586, 560-566	50.4	299
25	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , 2020 , 183, 429-441.e16	56.2	67
24	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. <i>Cell</i> , 2020 , 183, 1070-1085.e12	56.2	224
23	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020 , 586, 567-571	50.4	594
22	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 26915-26925	11.5	49
21	Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross. <i>Cell Reports</i> , 2020 , 31, 107587	10.6	9
20	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. <i>EBioMedicine</i> , 2020 , 62, 103132	8.8	39

19	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. <i>Science</i> , 2020 , 370, 1464-1468	33.3	517
18	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 29832-29838	11.5	57
17	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020 , 183, 1367-1382.e17	56.2	217
16	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020 , 13,	4.1	26
15	H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice. <i>Virology Journal</i> , 2020 , 17, 56	6.1	6
14	Genetically Engineering a Susceptible Mouse Model for MERS-CoV-Induced Acute Respiratory Distress Syndrome. <i>Methods in Molecular Biology</i> , 2020 , 2099, 137-159	1.4	11
13	Increasing the translation of mouse models of MERS coronavirus pathogenesis through kinetic hematological analysis. <i>PLoS ONE</i> , 2019 , 14, e0220126	3.7	9
12	Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis. <i>Journal of General Virology</i> , 2019 , 100, 1073-1078	4.9	19
11	Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. <i>Journal of Virology</i> , 2018 , 92,	6.6	48
10	Giving the Genes a Shuffle: Using Natural Variation to Understand Host Genetic Contributions to Viral Infections. <i>Trends in Genetics</i> , 2018 , 34, 777-789	8.5	14
9	Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. <i>MBio</i> , 2018 , 9,	7.8	431
8	Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. <i>Mammalian Genome</i> , 2018 , 29, 367-383	3.2	14
7	Of mice and men: the host response to influenza virus infection. <i>Mammalian Genome</i> , 2018 , 29, 446-470	3.2	12
6	Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. <i>MSphere</i> , 2017 , 2,	5	71
5	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	983
4	Influenza H3N2 infection of the collaborative cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice. <i>BMC Genomics</i> , 2016 , 17, 143	4.5	33
3	Lst1 deficiency has a minor impact on course and outcome of the host response to influenza A H1N1 infections in mice. <i>Virology Journal</i> , 2016 , 13, 17	6.1	4
2	In vivo knockdown of Piccolino disrupts presynaptic ribbon morphology in mouse photoreceptor synapses. <i>Frontiers in Cellular Neuroscience</i> , 2014 , 8, 259	6.1	31

1	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>SSRN Electronic Journal</i> ,	1	11
---	--	---	----